Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...

ENDURANCE randomized 516 standard-risk, transplant-deferred patients after PI–lenalidomide induction to indefinite vs 2-year lenalidomide maintenance, powered for a 50% median OS improvement.

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...

Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Chronic stress biomarker allostatic load links to higher under-50 cancer risk, offering a simple lab-based tool to improve prevention and screening. ASCO 2026 highlights breast cancer care: gene tests ...

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...